Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Phase 2TerminatedNCT00799942

Merz Pharmaceuticals GmbH48 enrolled

Overview

The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nystagmus, Congenital Nystagmus, Acquired Multiple Sclerosis

Interventions

Neramexane mesylateDRUG

open-label treatment of 36 months Neramexane mesylate up to 75 mg per day

Eligibility

Sex: ALLMin age: 18 YearsMax age: 81 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients who has succesfully completed the lead-in study MRZ 92579-0707/1 Exclusion Criteria: * Occurence of any major treatment-emergent adverse event or condition during the previous protocol (MRZ 92579-0707/1)

Locations (1)

University of Leicester, Leicester Royal Infirmary, Ophthalmology Group

Leicester, United Kingdom

Outcomes

Primary Outcomes

Long-term safety, Visual acuity

Time frame: Baseline, week 4, month 3, 6, 9, 12, 18, 24, 30, 36 and follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.